Conduit Pharmaceuticals Files Definitive Proxy Statement

TL;DR

Conduit Pharma (formerly Murphy Canyon Acquisition) filed its proxy statement. Shareholders vote soon.

AI Summary

Conduit Pharmaceuticals Inc. filed its definitive proxy statement on October 28, 2024, for the fiscal year ending December 31, 2024. The company, formerly known as Murphy Canyon Acquisition Corp. until November 30, 2021, is headquartered at 4995 Murphy Canyon Road, Suite 300, San Diego, CA 92123. This filing is related to the company's proxy solicitation under Section 14(a) of the Securities Exchange Act of 1934.

Why It Matters

This filing provides shareholders with essential information regarding upcoming shareholder meetings and voting matters, allowing them to make informed decisions about the company's governance.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not contain new financial information or significant corporate actions that would inherently increase risk.

Key Numbers

• 20241028 — Filing Date (Date the definitive proxy statement was filed with the SEC.)
• 1231 — Fiscal Year End (Indicates the end of the company's fiscal year for reporting purposes.)

Key Players & Entities

• CONDUIT PHARMACEUTICALS INC. (company) — Registrant
• Murphy Canyon Acquisition Corp. (company) — Former Company Name
• 4995 Murphy Canyon Road, Suite 300 (location) — Business Address
• San Diego, CA (location) — Business Address City and State

FAQ

Key Financial Figures

• $0 — holders of our common stock, par value $0.0001, (the “Common Stock”)

Filing Documents

• formdef14a.htm (DEF 14A) — 408KB
• formdef14a_001.jpg (GRAPHIC) — 9KB
• proxy_001.jpg (GRAPHIC) — 2411KB
• proxy_002.jpg (GRAPHIC) — 2847KB
• 0001493152-24-042718.txt ( ) — 7662KB

From the Filing

DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 CONDUIT PHARMACEUTICALS INC. (Name of Registrant as Specified in its Charter) N/A (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. 4995 Murphy Canyon Road, Suite 300 San Diego, California 92123 (760) 471-8536 NOTICE OF VIRTUAL ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON WEDNESDAY, DECEMBER 18, 2024 To our stockholders: The 2024 virtual annual meeting of stockholders (the “2024 Annual Meeting”) of Conduit Pharmaceuticals Inc., a Delaware corporation, will be held on Wednesday, December 18, 2024 at 10:00 a.m., Eastern Time, for the following purposes: 1. to elect six directors, each for a one-year term expiring at our next annual meeting of stockholders and until each such director’s successor is elected and qualified (Proposal No. 1); 2. to ratify the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 (Proposal No. 2); and 3. to adopt and approve an amendment to our Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of issued shares of the Company’s common stock into a lesser number of shares by a ratio of not less than 1-for-10 and not more than 1-for-100, with the exact ratio to be set within this range by the Board of Directors of the Company (the “Board”) in its sole discretion, in the form attached as Annex A to this proxy statement (Proposal No. 3) ; and 4. to transact such other matters as may properly come before the 2024 Annual Meeting or any adjournment or postponement thereof. Only holders of record of our common stock as of the close of business on October 25, 2024, the record date, are entitled to notice of and to vote at the 2024 Annual Meeting. The 2024 Annual Meeting will be a completely “virtual” meeting of stockholders. You will be able to listen and participate in the virtual annual meeting as well as vote and submit your questions during the live webcast of the meeting by registering in advance of the 2024 Annual Meeting at https://meeting.vstocktransfer.com/2024conduit. A Zoom account is required to register. If your shares are held by a bank, broker or other agent, please follow the instructions from your bank, broker or other agent to have your shares voted. Whether or not you plan to participate virtually in the 2024 Annual Meeting, your vote is important. To assure your representation at the meeting, please vote by following the instructions on the document that has been mailed to you, or, if you received a paper copy of the proxy materials, signing and dating the enclosed proxy card and returning it promptly in the enclosed postage-paid envelope. Sending in your proxy or submitting voting instructions via the Internet will not prevent you from voting during the 2024 Annual Meeting. If you vote during the 2024 Annual Meeting pursuant to the voting instructions below, that vote will revoke any prior proxy or voting instructions that you have submitted. By Order of the Board of Directors, /s/ Dr. David Tapolczay Dr. David Tapolczay Chief Executive Officer San Diego, California October 28, 2024 1 IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2024 VIRTUAL ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 18, 2024 This Proxy Statement, the Proxy Card and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 are available online at: https://ts.vstocktransfer.com/irhlogin/I-CONDUIT 2 4995 Murphy Canyon Road, Suite 300 San Diego, California 92123 (760) 471-8536 PROXY Conduit Pharmaceuticals Inc. is furnishing this proxy statement to our stockholders of record as of the close of business on October 25, 2024 (the “Record Date”) in connection with our solicitation of proxies for use at the virtual annual meeting of stockholders to be held on Wednesday, December 18, 2024 at 10:00 a.m., Eastern Time and any adjournment(s), postponement(s) or other delays thereof (the “2024 Annual Meeting”). The 2024 Annual Meeting will be a completely “virtual” meeting of stockholders. You will be able to listen and participate in the virtual annual

View Full Filing

View this DEF 14A filing on SEC EDGAR